#Alkermes (ALKS)

Alkermes in the NEWS Today, Alkermes Inc., ( ALKS ) announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 ( NT1 ). Alixorexton...

The Week in Review #26 IN THE BIOTECH WORLD -  RESEARCH -  IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its...

DIABETES From the 72 nd  Scientific Sessions of the American Diabetes Association ADA in Philadelphia AMYLIN (AMLN ) POSITIVE RESULTS FOR SYMLIN ® In  Type 2 And Type 1 Diabetes Results from new analy...

Elan (ELN):  Around $381 million found their way into Elan’s coffers. The money is the net proceeds from the sale of 76% (24.15 million ordinary shares) of its shareholding in  Alkermes (ALKS) , net o...